Pharma Focus Asia

Pharma Press Releases

Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.

Actelion applies for EMA approval of OPSUMIT ® (macitentan) for the treatment of chronic thrombo-embolic pulmonary hypertension (CTEPH)

Friday, August 31, 2018

Actelion Pharmaceuticals Ltd part of the Janssen Pharmaceutical Companies of Johnson Johnson announced today the submission of a Type II indication for the European Medicines Agency EMA The approval is intended to expand the indication for OPSUMIT...

United Therapeutics Corporation Completes Acquisition Of SteadyMed Ltd.

Friday, August 31, 2018

United Therapeutics Corporation today announced that it has closed the merger of SteadyMed Ltd with a subsidiary of United Therapeutics Pursuant to the merger United Therapeutics acquired all of the outstanding ordinary shares of SteadyMed As a resul...

Medical, healthcare and MedTech innovations take centre stage at Asia’s leading exhibitions – MEDICAL FAIR ASIA & MEDICAL MANUFACTURING ASIA 2018

Thursday, August 30, 2018

MEDICAL FAIR ASIA and MEDICAL MANUFACTURING ASIA was opened today by Dr Koh Poh Koon Senior Minister of State for Trade and Industry at the Marina Bay Sands Singapore Open to trade professionals and all those involved in the medical and healthcare...

SOTIO and PPF Complete Acquisition of Cytune Pharma

Thursday, August 30, 2018

SOTIO a biotechnology company owned by the PPF Group announces today the completion of the acquisition of Cytune Pharma by PPF SOTIO will continue to develop the lead program SOC RLI within its pipeline and intends to initiate firstinhuman clinical t...

Adverum Biotechnologies Announces IND Active for ADVM-022, a Novel Gene Therapy to Treat Wet Age-related Macular Degeneration

Thursday, August 30, 2018

Adverum Biotechnologies Inc a clinicalstage gene therapy company targeting unmet medical needs in serious rare and ocular diseases today announced its Investigational New Drug IND application is active for the planned multicenter openlabel Phase dos...

Impel NeuroPharma Annouces First Subject Dosed In Phase 1 Trial Evaluating INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia

Thursday, August 30, 2018

Impel NeuroPharma a Seattlebased privatelyheld biopharmaceutical company focused on therapies for the treatment of central nervous system CNS disorders today announced the first subject has been dosed in a Phase randomized doubleblind placeboandacti...

GT Biopharma Announces Initiation of OXS-1550 in Combination With a Multi-billion Dollar Oncology Drug

Wednesday, August 29, 2018

GT Biopharma Inc GTBP announced today the initiation of a combination trial of OXS and multibillion dollar oncology drug owned by a major Pharmaceutical Company the Company This effort is headed by Dr Daniel Vallera Director Section of Molecular Canc...

MeiraGTx Announces AAV-CNGA3 Granted Rare Pediatric Disease Designation by the U.S. FDA for the Treatment of Achromatopsia

Tuesday, August 28, 2018

MeiraGTx Holdings Plc a vertically integrated clinical stage gene therapy company today announced that the Offices of Orphan Products Development and Pediatric Therapeutics of the US Food and Drug Administration FDA have granted rare pediatric diseas...

BeiGene Announces Acceptance of its First New Drug Application for Zanubrutinib in Relapsed/Refractory Mantle Cell Lymphoma by China Drug Administration

Tuesday, August 28, 2018

BeiGene Ltd a commercialstage biopharmaceutical company focused on developing and commercializing innovative molecularlytargeted and immunooncology drugs for the treatment of cancer today announced the acceptance by the China Drug Administration CDA...

Peptilogics Completes Successful Pre-IND Meeting With the Food and Drug Administration (FDA) for PLG0206 in Prosthetic Joint Infections (PJI)

Monday, August 27, 2018

Peptilogics a development stage company utilizing its innovative peptide platform to treat multidrugresistant bacterial infections today announced it recently held a preInvestigational New Drug preIND meeting with the US Food and Drug Administration...